Executive Summary

The medical technology (medtech) industry is entering a period of accelerated change, driven by structural forces across global pricing, care delivery, supply chains, and enabling technologies. This analysis examines five key trends identified in a recent industry report that are expected to shape market dynamics in 2026: the expansion of China's volume-based procurement (VBP), the shift of procedures to outpatient settings, supply chain pressures reshaping manufacturing strategy, the impact of GLP-1 therapies on care pathways, and the emergence of platform-based competition. Each trend carries significant implications for multinational corporations, healthcare providers, and investors operating in the global medical device market.

Introduction

The global medtech industry is navigating a complex environment where policy changes, technological innovation, and shifting care models intersect. For executives and investors, understanding these forces is critical for strategic planning. This article provides an overview of five trends from Clarivate's "Medtech Trends to Watch in 2026" report, analyzing their global significance and potential long-term impact.

Background

The medtech sector has long been characterized by steady technological advancement and regulatory evolution. However, recent developments—ranging from China's procurement reforms to the rapid adoption of GLP-1 drugs—are accelerating the pace of change. These trends are not isolated; they reflect broader shifts in global healthcare economics and delivery.

Main Analysis

1. Mainland China's VBP Expansion Redefining Global Market Economics

China's national volume-based procurement (VBP) program has evolved into a powerful market-structuring mechanism. The latest rules introduce more sophisticated anchor-price logic, deeper price compression, and allocation systems that favor domestic manufacturers. For multinational medtech companies, VBP now influences pricing expectations beyond China, affecting global portfolio strategy and competitive positioning. The program aims to expand patient access but also accelerates domestic innovation, challenging foreign firms to adapt their business models.

2. Outpatient and ASC Settings Becoming Central to Procedure Strategy

The migration of procedures from hospitals to ambulatory surgical centers (ASCs) is accelerating, particularly in the United States. The CMS 2026 Hospital Outpatient Prospective Payment System (OPPS) and ASC Payment System Final Rule expands the ASC Covered Procedure List, allowing higher-acuity procedures like cardiac ablation to be performed in lower-cost settings. This shift requires medtech companies to redesign commercial models and product value propositions to meet the needs of diverse sites of care.

3. Global Trade and Supply Chain Pressures Reshaping Manufacturing Strategy

Tariff exposure, geopolitical tensions, and material cost fluctuations are challenging assumptions about where and how medical devices should be manufactured. In response, companies are diversifying sourcing, adopting multi-region manufacturing footprints, and leveraging scale and technology to buffer against volatility. Supply chain resilience has become a strategic imperative, with implications for cost structures and competitive advantage.

4. GLP-1 Therapies Shifting Patient Behavior and Care Pathways

The rapid adoption of GLP-1 receptor agonists for weight management is altering referral patterns and influencing demand across adjacent medtech categories. While bariatric surgery remains the most effective intervention for substantial weight loss, GLP-1s are reshaping how metabolic disease is managed. Downstream effects on diabetes care, sleep apnea, and cardiovascular monitoring are only beginning to emerge, creating both challenges and opportunities for device makers.

5. Enabling Technologies Driving Platform-Based Competition

Robotics, imaging, navigation, and digital workflow software are becoming central to integrated ecosystems that support clinical planning, surgical execution, and postoperative care. Companies are investing in platform architectures to anchor service lines and unlock data-driven value propositions. Emerging open-platform systems are expanding flexibility, redefining how value is delivered to customers.

Global Significance

These trends have profound implications beyond individual markets. China's VBP is influencing global pricing norms, while the shift to ASCs is transforming healthcare delivery in the U.S. and other countries with similar policy trends. Supply chain pressures are prompting a global re-evaluation of manufacturing strategies, and GLP-1 therapies are affecting patient populations worldwide. Platform-based competition is fostering innovation ecosystems that transcend national borders. Together, these forces are reshaping the global medtech competitive landscape.

Strategic Insights

For companies in the medtech space, several strategic priorities emerge:

• Portfolio Adaptation: Diversify portfolios to align with price pressures and shifting care settings.
• Supply Chain Resilience: Develop flexible, multi-region manufacturing strategies.
• Platform Investments: Build integrated technology ecosystems to enhance customer lock-in.
• Therapeutic Synergies: Monitor the ripple effects of GLP-1 adoption on device demand.

Investors should evaluate these trends when assessing market opportunities, particularly in regions affected by procurement reforms and outpatient migration.

Future Outlook

Looking ahead 3–10 years, these trends will likely intensify. China's VBP will continue to evolve, potentially expanding to more device categories. ASC adoption may become a global model for cost-effective care. Supply chain diversification will persist as geopolitical uncertainty remains. GLP-1 therapies could redefine metabolic disease management, reducing the need for some surgical interventions while creating demand for monitoring technologies. Platform-based competition will likely become the dominant paradigm, with companies differentiating through integrated digital ecosystems. The medtech industry must remain agile to thrive in this dynamic environment.

Conclusion

The five medtech trends outlined above represent critical inflection points for the industry. By understanding these developments, stakeholders can make informed decisions to navigate the changing landscape. The convergence of policy, technology, and care delivery models will continue to shape the future of medical technology, demanding strategic foresight and adaptability.

---

This article is based on insights from Clarivate's "Medtech Trends to Watch in 2026" report. Read the original research: Medtech Trends to Watch in 2026

Key Takeaways

• China's VBP expansion is redefining global medtech pricing and competition.
• The shift to outpatient and ASC settings is altering procedure strategies.
• Supply chain pressures are prompting diversified manufacturing.
• GLP-1 therapies are reshaping care pathways with cross-sector effects.
• Platform-based competition is becoming the key differentiator.

SEO Keywords

Medtech trends 2026, medical technology industry, China VBP, ambulatory surgical centers, supply chain resilience, GLP-1 therapies, platform-based competition, global healthcare markets, medical device manufacturing, digital health trends.

Sources

• Clarivate. (2026). Medtech Trends to Watch in 2026. [online] Available at: https://clarivate.com/life-sciences-healthcare/blog/5-medtech-trends-to-watch-in-2026